COSA 2021: Lenvatinib + Pembrolizumab Shows Promise Against Advanced Melanoma
Efficacy and safety were demonstrated irrespective of primary or secondary resistance.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.